W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.
Xiao X. Wei,Rana R. McKay,Kathryn P. Gray,Walter M. Stadler,David F. McDermott,Bradley Alexander McGregor,Neeraj Agarwal,Christos Kyriakopoulos,Benedito A. Carneiro,Tracy L. Rose,Yousef Zakharia,David A. Braun,Kenneth J. Livak,Catherine J. Wu,Eliezer M. Van Allen,Sabina Signoretti,Joshua Michael Lang,F. Stephen Hodi,Toni K. Choueiri,Lauren C. Harshman +19 more
TL;DR: This clinical trial aims to establish NIVO as a standard of care (SOC) option for advanced clear cell RCC (ccRCC) after prior antiangiogenic therapy and to evaluate the combination of IPI plus N IVO with the aim of finding a single agent to treat patients with advanced RCC.
Journal ArticleDOI
Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS).
Rashmi Chugh,Kent A. Griffith,Bruce Brockstein,Samir D. Undevia,Walter M. Stadler,Scott M. Schuetze +5 more
TL;DR: A dose escalation study of C with D in STS, where anti-IGF1R antibody cixutumumab has shown acceptable toxicity in a single-agent phase 2 study of STS and the TITE-CRM method was used to estimate the probability of DLT at each dose level.
Journal ArticleDOI
Long-term follow up after non-myeloablative allogeneic stem cell transplantation for renal cell carcinoma: the university of Chicago experience
Andrew S. Artz,K. van Besien,Todd M. Zimmerman,Thomas F. Gajewski,Brian I. Rini,S. Hu,Walter M. Stadler,N. J. Vogelzang +7 more
Journal ArticleDOI
Variability in surgical quality in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy
Seth P. Lerner,John P. Stein,Walter M. Stadler,Susan Groshen,Ellenie Tuazon,Donald G. Skinner,Derek Raghavan,David Esrig,Gary D. Steinberg,Laurence Klotz,Craig Hall,Richard J. Cote +11 more
Journal ArticleDOI
A phase II trial of gemcitabine(G), capecitabine (C), and bevacizumab (B) in patients (pts) with metastatic renal cell carcinoma (RCC)
Elizabeth K. Chung,Edwin M. Posadas,Kristen Kasza,Theodore Karrison,Elizabeth Manchen,L. Michalak,Olwen Hahn,Walter M. Stadler +7 more
TL;DR: The trial was terminated early despite not meeting protocol criteria for success or futility due to slow accrual and the fact that the historical response rate on which the trial was based became irrelevant with emerging data using sequential VEGF pathway directed therapies.